Concerned about NASDAQ criteria for uplisting...
I am currently an investor in Ekso bionics and believe the company has a lot to offer. However, I am concerned about a comment that Brett posted on June 8th on totalwealthresearch.com's article "what ekso's latest move means for your money." A lot of hype has surrounded ekso's 30 days above $4/share. However, Ekso also needs to meet NASDAQ requirements for average trading numbers, pre-tax earnings, cash flow, and revenue - all of which Ekso allegedly falls short on. I have been waiting for Keith to address Brett's post - but he hasn't. I am a novice investor and am long Ekso. However, I'm getting a little nervous about how no one has addressed this and have considered selling my shares. Am I missing something? Any input would be greatly appreciated.
Thank you.